Similar to our in vivo results using dAd/shErbB3, oAd/shErbB3-treated breast tumors exhibited a markedly lower number of PCNA-positive cells, higher number of TUNEL-positive cells, and decreased level of ErbB3 compared to tumors that were treated with PBS or oAd. The gene discussed is ERBB3; the disease is breast neoplasm.